Myocarditis With COVID-19 mRNA Vaccines

Area of Science:

• Cardiology
• Immunology
• Vaccinology

Background:

• Myocarditis is a rare complication following COVID-19 mRNA vaccination, observed predominantly in adolescent and young adult males.
• Reported cases show consistent symptoms like chest pain post-vaccination, with abnormal ECG and cardiac MRI findings suggestive of myocarditis.

Purpose of the Study:

• To review the characteristics, potential mechanisms, and clinical outcomes of myocarditis following COVID-19 mRNA vaccination.
• To assess the benefit-risk balance of COVID-19 vaccination in light of rare myocarditis cases.

Main Methods:

• Analysis of reported cases of myocarditis post-COVID-19 mRNA vaccination.
• Review of clinical presentation, diagnostic markers (cardiac troponin, ECG, cardiac MRI), and etiological investigations.
• Examination of proposed pathomechanisms, including molecular mimicry and immune dysregulation.

Main Results:

• Myocarditis cases presented with chest pain 2-3 days after the second vaccine dose, showing elevated troponin, ST elevations on ECG, and positive cardiac MRI.
• No evidence of acute COVID-19 or other viral infections was found; one case showed increased autoantibodies and natural killer cells.
• Most patients experienced symptom resolution and improved diagnostic markers with or without treatment.

Conclusions:

• COVID-19 mRNA vaccination is associated with rare cases of myocarditis, primarily in young males, with generally favorable outcomes.
• Potential mechanisms include molecular mimicry and immune system activation, with male predominance possibly linked to hormonal differences.
• The overall benefit-risk assessment strongly favors COVID-19 vaccination for individuals aged 12 and older.